Rainbow Children's Medicare Limited has announced the grant of 1,00,000 stock options to its eligible employees under the Employee Stock Option Scheme 2025. The Nomination and Remuneration Committee approved this grant during its meeting held on January 28, 2026, as disclosed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Stock Option Grant Details

The comprehensive details of the stock option grant are structured as follows:

Vesting and Exercise Terms

The stock options come with specific vesting and exercise conditions designed to align employee interests with company performance. The vested stock options can be exercised within a maximum period of 2 years from the date of each vesting. The vesting schedule allows stock options to vest after a minimum period of 1 year but not later than the maximum period of 10 years from the grant date.

Pricing Structure

The exercise price for the granted options has been determined using a market-linked pricing formula. The options were granted at an exercise price set at a discount of not more than 20% on the latest available closing price of the company's equity shares on the National Stock Exchange of India Limited, which is the stock exchange with the highest trading volume for the company's shares.

Previous Grant Cancellations

The company also reported cancellations from previous grants, with 6,430 stock options that were granted during the Nomination and Remuneration Committee meeting held on July 26, 2025, now standing cancelled. These cancellations occurred due to the exit of respective employees prior to completion of the vesting period, demonstrating the performance-linked nature of the scheme.

Regulatory Compliance

The Employee Stock Option Scheme 2025 operates in full compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The disclosure was made in accordance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring transparency and regulatory adherence in the stock option grant process.

Rainbow Childrens Medicare has reported its Q3 consolidated financial results, demonstrating positive growth in profitability compared to the corresponding quarter of the previous year. The pediatric healthcare chain achieved consolidated net profit of ₹725 million during the quarter.

Financial Performance Overview

The company's Q3 consolidated net profit showed year-on-year improvement, with the following performance metrics:

The ₹725 million consolidated net profit represents a growth of ₹38 million compared to the ₹687 million reported in Q3 of the previous year. This translates to a year-on-year growth rate of approximately 5.5%, indicating steady improvement in the company's financial performance.

Business Performance Analysis

The positive growth in consolidated net profit reflects the company's operational efficiency and business expansion during the quarter. Rainbow Childrens Medicare's ability to increase profitability demonstrates the healthcare provider's strong market position in the pediatric care segment.

The year-on-year comparison shows consistent performance improvement, with the company successfully enhancing its bottom-line results. This growth trajectory indicates effective management of operational costs and revenue optimization strategies implemented by the healthcare chain.

Market Position

The Q3 results position Rainbow Childrens Medicare favorably in the healthcare sector, particularly in specialized pediatric care services. The company's ability to maintain positive growth momentum reflects its operational strength and market demand for quality healthcare services.